MT-2990 is under clinical development by Mitsubishi Tanabe Pharma and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis). According to GlobalData, Phase I drugs for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MT-2990’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MT-2990 overview

MT-2990 is under development for the treatment of endometrial related pain, antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV) and seasonal allergic rhinitis. It is administered  through intravenous route. The therapeutic candidate is a fully human anti-IL33 monoclonal antibody. It was also under development for the treatment of autoimmune disorders.

Mitsubishi Tanabe Pharma overview

Mitsubishi Tanabe Pharma (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures, and commercializes ethical drugs and over-the-counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders, and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe also offers major products for skin conditions and digestive medicines. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe, and North America. Mitsubishi Tanabe is headquartered in Osaka, Japan.

For a complete picture of MT-2990’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.